Background: Type 2 Diabetes mellitus (T2DM) serious health threat affecting the group as essentially every country around the globe, with the prevalence of Type-2 Diabetes.T2DM taking place over a long period of time to the peripheral insulin resistance appropriate to the inactivation of the Insulin Receptor protein. Elucidated compounds should be evaluated in favor of the use of an antidiabetic in-silico docking study. Active site and pocket-finder apparatus shall be analyzed for the receptor. Amino acids were predicted to be active site binding residues. Docking studies were carried out during the Schrödinger software system. Aim: To the present study identified omega-3 PUFAs (EPA DHA & AA) Compounds while important blocker of hydrophobic pocket throughout molecular modeling study beside Type2 Diabetes. Materials and Methods: A group of three analog VDRs are being developed for discovery treatment with a type 2 diabetes inhibitor. Its use as a molecular docking study was to recognize the binding method involving the compound in T2diabetes through ADMET prediction. Whether to predict binding energy in the MMGBSA test. The molecular dynamic stimulation was enhanced by conformation within the strength of the possible composite binding. The PUFAs (EPA, DHA & AA) derived contain experience to Type 2 diabetes Results and Discussion: Based on the computational results, the Omega-3 and Omega-6 PUFAs EPA, DHA & AA compounds encourage energy interaction. Composite contains an in-vitro antidiabetic assay; the compounds must be clearly shown that it is active on type 2 diabetes. Conclusion: Our studies provide vital information on the findings of biomolecules of type 2 diabetes inhibitors.

Key words: Type 2 Diabetes Mellitus (T2DM), Polyunsaturated fatty acids, Vitamin D Receptor, EPA, DHA, AA.